Siirt Üniversity Medical Faculty
Siirt, 56000, Turkey (Türkiye)
NCT Number: NCT05446025
Hyperemesis gravidarum is a disease of unknown etiology that is frequently encountered in pregnant women and seriously impairs their quality of life. In the United States, hyperemesis gravidarum is the most common cause of hospitalizations in the first half of pregnancy and is second only to preterm labor for hospitalizations during pregnancy overall. The prevalence of hyperemesis gravidarum is approximately 0.3-3% of pregnancies and varies due to different diagnostic criteria and ethnic differences in study populations. According to the latest guidelines from the American College of Obstetricians and Gynecologists (ACOG) on nausea and vomiting during pregnancy, there is still no single accepted definition for hyperemesis gravidarum. The most commonly cited criteria for the diagnosis of hyperemesis gravidarum include persistent, unrelated to other causes, ketonuria, electrolyte abnormalities and acid-base disturbances, as well as weight loss. Weight loss is usually stated as at least 5% loss. In normal individuals, the appetite regulation center is the hypothalamus. Neuropeptides released from hypothalamic neurons play an important role in the regulation of nutrition by acting both in the hypothalamus and other appetite-regulating centers in the brain. Among the neuropeptides that are secreted by the central nervous system and peripheral organs and also play an important role in the regulation of energy and appetite, there are neuropeptides known as orexigenic neuropeptides, which reduce energy expenditure and increase appetite, as well as anorexigenic neuropeptides, which, on the contrary, reduce appetite and increase energy expenditure. It is known that disorders in these pathways cause pathologies in appetite and food intake in normal individuals. In our study, we plan to examine the levels of some neuropeptides in patients with hyperemesis gravidarum in order to investigate whether these pathways are affected or not. In this study, we aimed to investigate whether orexigenic neuropeptides (Orexin, Galanin) and anorexigenic neuropeptides (aMSH, CART) levels are associated with hyperemesis gravidarum.
Looking for future studies?
Notify Me18 year–50 year
Female
Observational
Siirt, 56000, Turkey (Türkiye)
Our aim in this study is to determine the levels of orexigenic and anorexigenic neuropeptides in patients with hyperemesis gravidarum and to determine whether there is a relationship between the function of the appetite center and the levels of these neuropeptides. For this purpose, approximately 50 pregnant women who were followed up with the diagnosis of hyperemesis gravidarum in Siirt Training and Research Hospital between 26 June 2022 and 30 october 2022 will be included in the study. The pregnant woman's age, pregnancy history, medical history will be recorded. Thyroid function test results, hemogram results and electrolyte levels of all patients will be recorded. Whole blood will be taken from these patients and the levels of Orexin and Galanin, which are orexigenic hormones, and aMSH and CART, which are anorexigenic hormones, will be checked. In the light of the information thus obtained, we plan to determine whether there is a relationship between hyperemesis gravidarum and the appetite center and between orexigenic and anorexigenic hormone levels.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
1-Inclusion Criteria:
5 to 20 weeks of pregnancy
Pregnants with a diagnosis of hyperemesis gravidarum
Pregnants who vomit more than 3 times a day
Those with 5 %more weight loss during pregnancy
detection of ketonuria
2-Exclusion Criteria:
food poisoning
Precision intestinal syndrome
Crohn's disease
Excessive alcohol consumption
Eating disorders such as anorexia and blomia
Neurological conditions such as meningitis, brain tumor and brain trauma
Migraine
Appendicitis
Chemotherapy drugs
Stomach and intestinal infections
Disorders such as celiac or lactose intolerance
-
Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured
Time frame: Up to 20th week of gestation
Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be examined in patients with hyperemesis gravidarum.(Blood hormones values will be measured by Elisa method(pg/mL)
Siirt University
Other
MSH and CART Levels of Orexigenic Hormones (Which Increase Appetite), Orexin, Galanin and Anorexigenic Hormones (Which Reduce Appetite) in Patients With Hyperemesis Gravidarum
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05098067
Female Urogenital Diseases and Pregnancy Complications, Hyperemesis Gravidarum
Providence, Rhode Island, United States
View Trial DetailsNCT04719286
Emesis, Emesis Pregnancy
Oslo, Norway
View Trial DetailsNCT04828967
Female Urogenital Diseases and Pregnancy Complications, Hyperemesis Gravidarum
Bursa, Yildirim/Bursa, Turkey (Türkiye)
View Trial DetailsNCT02163434
Female Urogenital Diseases and Pregnancy Complications, Hyperemesis Gravidarum
Buffalo, New York, United States
View Trial Details